PMID- 23811951
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20231213
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 27
IP  - 8
DP  - 2013 May 15
TI  - HLA-E variants are associated with sustained virological response in 
      HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
PG  - 1231-8
LID - 10.1097/QAD.0b013e32835f5b9c [doi]
AB  - OBJECTIVES: To analyze whether human leukocyte antigen (HLA)-E allelic variants 
      are associated with and may predict response to peg-interferon (IFN) alpha and 
      ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients. DESIGN: 
      Retrospective follow-up study. METHODS: We studied 321 naive patients who started 
      HCV treatment. HLA-E genotyping was performed by restriction fragment length 
      polymorphism. A sustained virological response (SVR) was defined as undetectable 
      plasma HCV-RNA up through 24 weeks after the end of HCV treatment. RESULTS: The 
      HLA-E*0101 allele increased the odds of achieving SVR for all patients [adjusted 
      odds ratio (aOR) = 2.03 (95% confidence interval, 95% CI = 1.35-3.06); 
      P = 0.001], for HCV genotype (GT) 1/4 patients (aOR = 1.62 (95% CI = 1.03-2.54), 
      P = 0.035), and for GT2/3 patients [aOR = 9.87 (95% CI = 2.47-31.89), P = 0.001]. 
      For decision tree analysis, the SVR rate increased from 0 to 82.6% and then to 
      92.5% in GT2/3 patients when the count of HLA-E*0101 alleles increased. In GT1/4 
      patients with rs8099917 TT genotype, the SVR rate increased from 33.3 to 54.8% 
      and then to 61.8% when the count of HLA-E*0101 alleles increased. In GT1/4 
      patients with rs8099917 GT/GG genotype, the SVR rate increased from 15.4 to 22% 
      and then to 44% when the count of HLA-E*0101 alleles increased. The overall 
      percentage of patients correctly classified was 73.2% and the area under the 
      receiver operating characteristic curve (AUROC) was 0.803 +/- 0.024. CONCLUSION: 
      The HLA-E*0101 allele was associated with increased odds of HCV clearance and 
      could help to predict SVR among HIV/HCV-coinfected patients on HCV therapy. This 
      would be helpful to avoid treatment in those less likely to respond to 
      pegylated-interferon-alpha and ribavirin treatment.
FAU - Guzman-Fulgencio, Maria
AU  - Guzman-Fulgencio M
AD  - Unidad de Coinfeccion HIV/Hepatitis, Centro Nacional de Microbiologia, Instituto 
      de Salud Carlos III, Majadahonda.
FAU - Berenguer, Juan
AU  - Berenguer J
FAU - Rallon, Norma
AU  - Rallon N
FAU - Fernandez-Rodriguez, Amanda
AU  - Fernandez-Rodriguez A
FAU - Miralles, Pilar
AU  - Miralles P
FAU - Soriano, Vicente
AU  - Soriano V
FAU - Jimenez-Sousa, Maria A
AU  - Jimenez-Sousa MA
FAU - Cosin, Jaime
AU  - Cosin J
FAU - Medrano, Jose
AU  - Medrano J
FAU - Garcia-Alvarez, Monica
AU  - Garcia-Alvarez M
FAU - Lopez, Juan C
AU  - Lopez JC
FAU - Benito, Jose M
AU  - Benito JM
FAU - Resino, Salvador
AU  - Resino S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Antiviral Agents)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antiviral Agents/*therapeutic use
MH  - Coinfection
MH  - Female
MH  - Follow-Up Studies
MH  - Genotyping Techniques
MH  - HIV Infections/*drug therapy/genetics
MH  - Hepatitis C, Chronic/*drug therapy/genetics
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*therapeutic use
MH  - Polymorphism, Single Nucleotide
MH  - Recombinant Proteins/therapeutic use
MH  - Retrospective Studies
MH  - Ribavirin/*therapeutic use
MH  - Viral Load
MH  - HLA-E Antigens
EDAT- 2013/07/03 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/07/02 06:00
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - 00002030-201305150-00005 [pii]
AID - 10.1097/QAD.0b013e32835f5b9c [doi]
PST - ppublish
SO  - AIDS. 2013 May 15;27(8):1231-8. doi: 10.1097/QAD.0b013e32835f5b9c.